EuroBiotech:​​ ​​More​​ ​​Articles​​ ​​of​​ ​​Note

A pile of newspapers

> Novo Nordisk paid Ablynx a €1 million ($1.1 million) milestone. The milestone, the first paid out under the deal the partners struck one year ago, follows the advance of a program to develop multispecific therapeutic proteins based on single-domain antibody fragments. Ablynx is aiming to get the candidate into the clinic in 2018. Release

> BerGenBio posted data from a phase 1/2 trial of its Axl kinase inhibitor in patients with advanced non-small cell lung cancer. Two of the eight patients who received the drug as a monotherapy had stable disease for at least six months. No patients experienced grade 3 or 4 adverse events. The next step is to test the drug in combination with Tarceva in EFGR mutant patients. Release

> A1M Pharma took another step toward moving its preeclampsia program into the clinic. The Swedish biotech now has maximum tolerated dose data from two animal models, teeing it up to assess the effect of repeat administrations. A1M expects to have data from the tests early next year and start GLP-compliant toxicology studies in the second quarter. Release


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> TopiVert secured clearance to trial its treatment of dry eye syndrome. The narrow spectrum kinase inhibitor specialist plans to start a phase 1/2 trial of its candidate in January. Release

> Shares in Genticel rose more than 125% after its multivalent vaccine partnership with Serum Institute of India progressed. The reengineered adenylate cyclase, GTL003, has cleared the last preclinical milestone, triggering a $1.2 million (€1.1 million) milestone and setting Serum Institute up to advance the candidate toward the clinic. Release

> Innate Pharma posted data from a dose-ranging study of monalizumab in patients with advanced gynecologic malignancies. The study gave monalizumab monotherapy to 18 patients. Safety data generated in that part of the phase 1/2 trial have encouraged Innate to start enrolling a 98-person expansion cohort and giving them the recommended dose. Release

Suggested Articles

China’s Biotheus picked up the rights to Tilt Biotherapeutics’ lead oncolytic virus program in greater China.

A Cedars-Sinai team used stem cells to uncover a key mechanism of young onset Parkinson's, as well as a potential remedy—an existing skin treatment.

The deal sets the stage for a push to build on recent phase 2b data and make the vaccine available in low-income countries where TB is prevalent.